TW374086B - Prostaglandin I2 agonistic oxazole compounds and the process for preparing thereof - Google Patents

Prostaglandin I2 agonistic oxazole compounds and the process for preparing thereof

Info

Publication number
TW374086B
TW374086B TW083111798A TW83111798A TW374086B TW 374086 B TW374086 B TW 374086B TW 083111798 A TW083111798 A TW 083111798A TW 83111798 A TW83111798 A TW 83111798A TW 374086 B TW374086 B TW 374086B
Authority
TW
Taiwan
Prior art keywords
agonistic
prostaglandin
preparing
oxazole compounds
formula
Prior art date
Application number
TW083111798A
Other languages
English (en)
Chinese (zh)
Inventor
Kiyoshi Taniguchi
Masanobu Nagano
Kazunori Tsubaki
Osamu Okitsu
Seiichiro Tabuchi
Tabuchi Seiichiro
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939325962A external-priority patent/GB9325962D0/en
Priority claimed from GB9422404A external-priority patent/GB9422404D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of TW374086B publication Critical patent/TW374086B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
TW083111798A 1993-12-20 1994-12-17 Prostaglandin I2 agonistic oxazole compounds and the process for preparing thereof TW374086B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939325962A GB9325962D0 (en) 1993-12-20 1993-12-20 Heterocyclic compounds
GB9422404A GB9422404D0 (en) 1994-11-07 1994-11-07 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
TW374086B true TW374086B (en) 1999-11-11

Family

ID=26304051

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083111798A TW374086B (en) 1993-12-20 1994-12-17 Prostaglandin I2 agonistic oxazole compounds and the process for preparing thereof

Country Status (17)

Country Link
US (1) US6025375A (hu)
EP (1) EP0736018B1 (hu)
JP (1) JPH09506894A (hu)
KR (1) KR100345943B1 (hu)
CN (2) CN1046714C (hu)
AT (1) ATE194335T1 (hu)
AU (1) AU686286B2 (hu)
CA (1) CA2179399A1 (hu)
DE (1) DE69425162T2 (hu)
DK (1) DK0736018T3 (hu)
ES (1) ES2147836T3 (hu)
GR (1) GR3034542T3 (hu)
HU (1) HUT76341A (hu)
PT (1) PT736018E (hu)
RU (1) RU2176640C2 (hu)
TW (1) TW374086B (hu)
WO (1) WO1995017393A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW401408B (en) * 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
IL141786A0 (en) 1998-09-17 2002-03-10 Bristol Myers Squibb Co A pharmaceutical composition for treating diabetes containing an ap2 inhibitor
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
ES2232434T3 (es) 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
CA2377593A1 (en) * 1999-06-21 2000-12-28 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
US7390824B1 (en) 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
DK1267867T3 (da) * 2000-03-24 2008-08-25 Asterand Uk Ltd Anvendelse af prostanoid-EP4-receptorantagonister til behandling af hovedpine og assays til sådanne antagonister
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2002085412A1 (fr) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la fibrose des tissus
TW200408621A (en) 2002-04-08 2004-06-01 Glaxo Group Ltd Compounds
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US8217027B2 (en) * 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
BRPI0807804A2 (pt) 2007-01-25 2014-06-17 Allergan Inc " arilciclopentenos substituídos como agentes terapêuticos ".
US9365485B2 (en) 2007-01-25 2016-06-14 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
AR076428A1 (es) * 2009-04-24 2011-06-08 Basf Se Compuestos de triazol que llevan un sustituyente de azufre iii
US8969573B2 (en) * 2010-06-28 2015-03-03 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation
WO2014194209A1 (en) 2013-05-31 2014-12-04 Allergan, Inc. Substituted cyclopentenes as therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
US4072689A (en) * 1973-02-22 1978-02-07 Gruppo Lepetit S.P.A. Monoamino 2,4,5-trisubstituted oxazoles
NZ236474A (en) * 1989-12-20 1993-07-27 Bristol Myers Squibb Co 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
KR100383305B1 (ko) * 1994-03-10 2003-11-01 후지사와 야꾸힝 고교 가부시키가이샤 프로스타글란딘i₂작용물질로서의나프탈렌유도체

Also Published As

Publication number Publication date
AU1200695A (en) 1995-07-10
KR960706482A (ko) 1996-12-09
CN1138328A (zh) 1996-12-18
CN1046714C (zh) 1999-11-24
CN1229795A (zh) 1999-09-29
GR3034542T3 (en) 2001-01-31
EP0736018B1 (en) 2000-07-05
ATE194335T1 (de) 2000-07-15
PT736018E (pt) 2000-10-31
RU2176640C2 (ru) 2001-12-10
JPH09506894A (ja) 1997-07-08
DK0736018T3 (da) 2000-09-18
US6025375A (en) 2000-02-15
WO1995017393A1 (en) 1995-06-29
DE69425162D1 (de) 2000-08-10
CA2179399A1 (en) 1995-06-29
EP0736018A1 (en) 1996-10-09
ES2147836T3 (es) 2000-10-01
HUT76341A (en) 1997-08-28
KR100345943B1 (ko) 2002-11-30
CN1090184C (zh) 2002-09-04
HU9601685D0 (en) 1996-08-28
AU686286B2 (en) 1998-02-05
DE69425162T2 (de) 2000-12-21

Similar Documents

Publication Publication Date Title
TW374086B (en) Prostaglandin I2 agonistic oxazole compounds and the process for preparing thereof
DE69831868D1 (en) Antithrombosemittel
TW369535B (en) A pyrazolopyridine compound and the process for preparing thereof
IL133623A0 (en) Antithrombotic agents
AU7116691A (en) Process for the preparation of oxetanones
AU664663B2 (en) Compounds useful as sweetening agents and process for their preparation
IE832654L (en) ß-LACTAM COMPOUNDS
CA2219747A1 (en) Aminothiazole derivative, medicament containing the same, and intermediate for preparation of said compound
AU5504694A (en) Substituted amic acid derivatives
AU7299694A (en) Azole compounds, their production and use
EP0997462A4 (en) NOVEL NAPHTHYRIDINE DERIVATIVES OR THEIR SALTS
EP0656356A4 (hu)
NZ240441A (en) Thiazol- or thiadiazol-substituted 7-acyl-3-substituted carbamoyloxy cephem derivatives and antibacterial compositions thereof; cephem intermediates
WO1998053790A3 (en) Compounds that inhibit the binding of vascular endothelial growth factor to its receptors
AU6257396A (en) Tetrahydrofuran antifungals
AU576530B2 (en) 1,3-dioxan-4-yl alkenoic acids
AU6306190A (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
GR3036403T3 (en) Process for the preparation of sulfonylurea derivatives and intermediates for this process
CA2309485A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
GR3025116T3 (en) Process for the preparation of n-carbonylarylimines useful for the synthesis of therapeutically active taxoids
HU9401003D0 (en) Process for producing new 4-androsteno[4,5-b]pyrrol derivatives
WO2003055879A3 (en) Tropane derivative, chelation product comprising this tropane derivative and a metal or a metal complex, and radiopharmaceutical
KR930017901A (ko) 카바세펨의 제조를 위한 신규한 방법 및 화합물
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii
GEP19981536B (en) Process for the Preparation of 1-Ethyl-1(Hydroxymethyl)-1,2,3,4,6,7,12,12-Octahydro-Indolo [2,3-) Quinolizine and Novel Intermediates ^